Pacific Biosciences of California, Inc.
PACB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.25 | 0.60 | -0.10 | 0.04 |
| FCF Yield | -42.25% | -10.77% | -15.25% | -2.81% |
| EV / EBITDA | -4.61 | -11.96 | -8.72 | -18.59 |
| Quality | ||||
| ROIC | -39.10% | -19.41% | -20.28% | -7.13% |
| Gross Margin | 24.21% | 26.32% | 38.22% | 45.10% |
| Cash Conversion Ratio | 0.67 | 0.87 | 0.84 | 0.61 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.28% | 15.39% | 17.60% | 12.82% |
| Free Cash Flow Growth | 20.81% | 4.33% | -139.21% | -734.27% |
| Safety | ||||
| Net Debt / EBITDA | -2.54 | -2.78 | -2.21 | -1.97 |
| Interest Coverage | -35.36 | -23.32 | -20.91 | -16.79 |
| Efficiency | ||||
| Inventory Turnover | 1.99 | 2.61 | 1.57 | 2.91 |
| Cash Conversion Cycle | 197.07 | 169.46 | 230.04 | 137.06 |